Non-coding RNAs in Alzheimer's disease: perspectives from omics studies

Erming Wang, Mariana Lemos Duarte, Lauren E. Rothman, Dongming Cai, Bin Zhang

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Neurodegenerative diseases such as Alzheimer's disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.

Original languageEnglish
Pages (from-to)R54-R61
JournalHuman Molecular Genetics
Volume31
Issue numberR1
DOIs
StatePublished - 15 Oct 2022

Fingerprint

Dive into the research topics of 'Non-coding RNAs in Alzheimer's disease: perspectives from omics studies'. Together they form a unique fingerprint.

Cite this